Haleon (HLN) Q1 2026 earnings review
Pricing Carries Top-Line as Volumes Turn Negative
Haleon's Q1 trading statement (which excludes bottom-line profit figures) paints a mixed picture. The company delivered 2.2% organic revenue growth, missing the run-rate needed for its 3-5% full-year target. The shortfall is primarily due to a weak cold and flu season, which dragged overall growth down by roughly 130 basis points. While management celebrated North America returning to growth (+1.0%), a closer look shows this was entirely driven by pricing (+3.7%) masking a steep volume decline (-2.7%). Oral Health remains the undisputed growth engine, but Haleon will need significant volume recovery in the coming quarters to hit its FY26 guidance.
🐂 Bull Case
If the 130 basis point headwind from the weak cold and flu season is excluded, underlying organic revenue growth would be 3.5%—landing squarely inside management's 3-5% full-year guidance range.
After a challenging FY25 plagued by retail destocking, North America finally returned to growth (+1.0%). Management expects this to accelerate through the year via shelf-resets and new innovation rollouts.
🐻 Bear Case
Total volume/mix was negative (-0.2%), driven heavily by a severe -2.7% volume contraction in North America. Growth is currently overly reliant on pricing actions.
Outside of Oral Health, the rest of the portfolio is dragging. Pain Relief (-0.3%), Respiratory Health (-3.4%), and Digestive Health (-0.4%) all posted negative organic growth in Q1.
⚖️ Verdict: ⚪
Neutral. The heavy reliance on Oral Health and pricing to offset volume declines is a concern. However, the temporary nature of the cold/flu headwind and the stabilization of North America suggest the second half of the year should see improvement.
Key Themes
Oral Health Remains the Undisputed Engine
Oral Health delivered a stable 8.3% organic growth, vastly outperforming every other category. The growth is fueled by premium innovation, specifically the continued rollout of the Sensodyne Clinical Repair platform and parodontax Gum Strengthen & Protect. In the US, these launches enabled Haleon to grow Oral Health at four times the market rate, proving strong consumer willingness to pay for premium, clinically-backed products.
North American Volumes Are Sinking
While North America technically reversed its decline to post +1.0% organic growth, the underlying composition is a major red flag. Price contributed +3.7%, but Volume/Mix was deeply negative at -2.7%. If pricing power wanes or consumer fatigue sets in, this region will quickly flip back into contraction.
Cold & Flu Shock Decimates Respiratory
A significantly weaker-than-expected cold and flu season created a ~130 bps drag on total company growth. Respiratory Health was the worst-hit category, decelerating further to -3.4%. Management noted double-digit declines in cold and flu products in North America, China, and Central & Eastern Europe. This highlights the inherent weather/seasonality risk in the OTC portfolio.
APAC E-commerce and Execution
APAC was the only region to deliver healthy, volume-led growth (Volume/Mix +3.7%, Price +0.3%). This was driven by excellent in-market execution in India (double-digit growth) and mid-single-digit growth in China, fueled heavily by e-commerce expansion and specific product tailoring, like Centrum Daily Kits designed for metabolism and cardio.
Brazil Macro Weakness Hurting LatAm
Latin America saw slowing growth due to a deteriorating macroeconomic environment in Brazil. This resulted in higher promotional activity to stay competitive, hurting pricing power and leading to targeted declines in brands like ENO. Management expects this to improve later in the year with activations around the FIFA World Cup 2026.
VMS Stabilization via Targeted Innovation
VMS growth is stabilizing (+1.7%) following post-pandemic volatility. A key driver was the launch of Centrum Nutrient Replenish in North America, specifically targeting GLP-1 users. Adapting to the rise of weight-loss drugs with targeted supplements shows agility in capturing new consumer trends.
Other KPIs
Haleon announced it has completed roughly 36% of its £500m share buyback program allocated for 2026. This aggressive early execution signals management's confidence in cash flow generation despite the top-line seasonal softness.
Reported revenue was nearly flat (+0.1%) due to a heavy 2.1% drag from translational foreign exchange, primarily the movement of the US Dollar against Pound Sterling. However, management revised FY26 FX guidance to be 'broadly neutral' based on updated forward rates.
Guidance
Accelerating. With Q1 coming in at 2.2%, the company must accelerate to a ~3.8% run-rate for the remaining three quarters to hit the midpoint. Management expects shelf-resets, increased distribution, and lapping the C&F drag to drive this H2-weighted acceleration.
Stable. Haleon reiterated this target, noting that supply chain productivity initiatives are currently driving strong gross margin improvements, which will fund the necessary growth investments while still delivering bottom-line expansion.
Key Questions
North America Volume Path
With North America volumes down 2.7% this quarter, what specific leading indicators give you confidence that shelf-resets and new distribution will translate to positive volume growth, rather than just masking the issue with pricing?
Pricing Power Limits
You achieved 3.7% pricing growth in North America despite lower volumes. As the consumer macro environment remains tight, how much more pricing power exists before elasticity forces a change in strategy?
Brazil Promotional Environment
You cited higher promotional activity in Brazil due to a weaker macro backdrop. Do you view this as a temporary blip, or a structural margin headwind for the LatAm region moving forward?